Business Development
Licensing
Ability Pharmaceuticals develops new drug candidates through clinical proof-of-concept, to later license them to pharmaceutical companies for further development and marketing.
Ability Pharmaceuticals is in-licensing new drug candidates from research institutions and other biotech and pharma companies, focusing in compounds that could be ready to start regulatory preclinical development in less than one year.
Ability Pharmaceuticals also establishes research collaborations with academic institutions to provide the company with an engine to generate new drug candidates and to build a competitive development pipeline.
In April 2016, AbilityPharma signed a territorial license agreement for ABTL0812 with the US company SciClone Pharmaceuticals to develop and market the product in Greater China, with upfront and milestone payments over $ 20 M
If you are interested in learning more on our products in development or you have a licensing opportunity which could be of our interest, please contact us :
Ability Pharmaceuticals is in-licensing new drug candidates from research institutions and other biotech and pharma companies, focusing in compounds that could be ready to start regulatory preclinical development in less than one year.
Ability Pharmaceuticals also establishes research collaborations with academic institutions to provide the company with an engine to generate new drug candidates and to build a competitive development pipeline.
In April 2016, AbilityPharma signed a territorial license agreement for ABTL0812 with the US company SciClone Pharmaceuticals to develop and market the product in Greater China, with upfront and milestone payments over $ 20 M
If you are interested in learning more on our products in development or you have a licensing opportunity which could be of our interest, please contact us :
LATEST NEWS
05.11.2020
Press Release
AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020
Press Release
AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020
Press Release
ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
09.06.2020
Press Release
AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020
Press Release
AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019
Press Release
AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019
Press Release
Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
04.02.2019
Press Release
Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
30.01.2019
Press Release
Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info
